ISSUE 22 - June 3, 2016 |
Seven years ago, when Congress sought to jumpstart the U.S. economy, few imagined that one aspect of the $800 billion stimulus program would turn electronic health records into the Tower of Babel.
Speaking at Memorial Sloan Kettering Cancer Center last week, Vice President Joe Biden took full responsibility for the major bioinformatics snafu triggered by the American Reinvestment and Recovery Act of 2009.
True, ARRA forced the U.S. medical establishment to digitize records in a hurry. Alas, today, fax machines and legions of data entry technicians are often required to transfer patient records from one hospital to another.
Biden said the Obama administration didn’t foresee the consequences of mandating the switch to EHRs without developing a standard infrastructure for aggregating data.
![]() |
Biden: "You're All Doing the Same Thing!" At a roundtable discussion at Memorial Sloan Kettering Cancer Center, Vice President Joe Biden urged greater efforts to aggregate cancer data. “I know MSK is part of Project GENIE and part of data sharing coalitions,” Biden said at the meeting May 26. “But I’ve met also with ORIEN, I’ve met with CancerLinQ.” “You’re all doing the same thing! I find it curious. I don’t know if that’s the only way it that can be done.” |
![]() |
University of Maryland Cancer Center
|
![]() |
ASCO Updates Value FrameworkThe American Society of Clinical Oncology published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms or quality of life in the context of cost. The updated framework will be the basis for a software tool that doctors can use to assist shared decision-making with their patients. The update was published in the Journal of Clinical Oncology. |
![]() |
Study: 70 Cancer Treatments Launched Over 5 Years Pushes Oncology Market to $107 BillionA study reviewing trends in oncology found that more than 20 tumor types are being treated with one or more of the 70 cancer treatments that have been launched in the past five years. The surge in new therapies drove the global oncology market to $107 billion in 2015, an 11.5 percent increase over the previous year in constant dollars. |
Funding OpportunityCDMRP Taking Pre-Applications
|
|
![]() |
Letter to the EditorProgress Against Cancer:
|
![]() |
In Brief
|
![]() |
Drugs and Targets
|